Axolotl Biologix specializes in advanced human amnion grafts designed for wound care and tissue repair. Their product offerings include the Axolotl Graft and DualGraft, which are engineered to enhance natural healing processes, providing faster and more effective results. The company emphasizes the importance of evidence-based practices, with their products supported by robust clinical research and peer-reviewed studies that validate their efficacy and safety. This commitment to quality is reflected in their adherence to high standards and their accreditation from the American Association of Tissue Banks (AATB), ensuring that their grafts are safe and effective for patient use.

The product portfolio of Axolotl Biologix is extensive, featuring various sizes and configurations to meet the diverse needs of healthcare providers and patients. Their offerings include both surgical and clinic products, with specific dimensions tailored for different applications in wound care. The company has established a strong presence in the market, with their products being utilized by clinicians across 44 states. Additionally, Axolotl Biologix is actively engaged in clinical trials to further substantiate the real-world outcomes of their grafts, reinforcing their dedication to advancing the field of tissue repair through innovative and evidence-based solutions.

United States

Axolotl Biologix, located in Arizona is a dynamic biotech company focused on developing and producing human biologics and biological-related products to reduce inflammation and foster regeneration for many conditions that affect patients, including orthopedic, wound care, cosmetic and more. Axolotl is currently negotiating partnerships with universities and research hospitals to find ways to improve current technologies and procedures to improve patients’ quality of life.

Axolotl Biologix

Company Details